TrialThe Lancet. Oncology2019

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.

Jason Fangusaro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.